MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: A single-institution study

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Shen, Dong ^a   Liu, Tao ^a   Lin, Qingfen ^a   Lu, Xiangdong ^a   Wang, Qiong ^a   Lin, Feng ^a   Mao, Weidong ^a  

^a University Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ALKYLATING AGENT; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; GLIOBLASTOMA; HAN CHINESE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; ADJUVANT CHEMORADIOTHERAPY; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; DNA SEQUENCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84944063563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107558     Document Type: Article

References (32)

1. Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, et al. (2009) Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Research 29: 2607-2610.
2. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, et al. (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. British Journal of Cancer 101: 124-131.
3. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal Of Medicine 352: 997-1003.
4. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatric Blood & Cancer 48: 403-407.
5. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, et al. (2011) Benefits of interferon-b and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117: 1721-1730.
6. Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, et al. (2012) Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research 18: 4070-4079.
7. Tang K, Jin Q, Yan W, Zhang W, You G, et al. (2012) Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Medical Oncology (Northwood, London, England) 29: 1292-1296.
8. Bady P, Sciuscio D, Diserens A-C, Bloch J, van den Bent MJ, et al. (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica 124: 547-560.
9. Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, et al. (2010) Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre study. Oncology Reports 23: 1655-1662.
10. Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, et al. (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 49: 1398-1405.
11. Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PHd, et al. (2011) Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (São Paulo, Brazil) 66: 1747-1755.
12. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, et al. (2010) MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: A comparative study on astrocytoma and glioblastoma. International Journal Of Cancer Journal International Du Cancer 127: 2106-2118.
13. Kim YS, Kim SH, Cho J, Kim JW, Chang JH, et al. (2012) MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: A single-institution study. International Journal Of Radiation Oncology, Biology, Physics 84: 661-667.
14. Chul-Kee P, Sung-Hye P, Se-Hoon L, Chae-Yong K, Dong-Wan K, et al. (2009) Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology 29: 443-449.
15. SteelFisher GK, Blendon RJ, Bekheit MM, Mitchell EW, Williams J, et al. (2011) Novel pandemic A (H1N1) influenza vaccination among pregnant women: motivators and barriers. American Journal of Obstetrics and Gynecology 204: S116-S123.
16. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, et al. (2009) Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 73: 1509-1510.
17. Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, et al. (2009) Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Journal Of Neuro-Oncology 92: 23-31.
18. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, et al. (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International Journal Of Cancer Journal International Du Cancer 131: 1342-1350.
19. Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, et al. (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32: 1220-1227.
20. Park C-K, Park S-H, Lee S-H, Kim C-Y, Kim D-W, et al. (2009) Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology: Official Journal Of The Japanese Society Of Neuropathology 29: 443-449.
21. Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold M-D, et al. (2012) O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118: 4545-4554.
22. Romano A, Calabria L, Tavanti F, Minniti G, Rossi-Espagnet M, et al. (2013) Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. European Radiology 23: 513-520.
23. Nehru GA, Pai R, Samuel P, Chacko AG, Chacko G (2012) Status of O6-methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. Neurology India 60: 481-486.
24. Della Puppa A, Persano L, Masi G, Rampazzo E, Sinigaglia A, et al. (2012) MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: A possible pitfall in stratification of patients? Journal Of Neuro-Oncology 106: 33-41.
25. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, et al. (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR American Journal Of Neuroradiology 33: 1349-1355.
26. Ellington SR, Hartman LK, Acosta M, Martinez-Romo M, Rubinson L, et al. (2011) Pandemic 2009 influenza A (H1N1) in 71 critically ill pregnant women in California. American Journal of Obstetrics and Gynecology 204: S21-S30.
27. Berghoff AS, Preusser M (2012) Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients-yes, but how? Clinical Neuropathology 31: 405-408.
28. Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, et al. (2011) Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. Journal Of Neurology, Neurosurgery, And Psychiatry 82: 441-446.
29. Christians A, Hartmann C, Benner A, Meyer J, Deimling Av, et al. (2012) Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. PLoS ONE 7: 1-9.
30. Niklas T (2011) Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. Journal of Neurology, Neurosurgery & Psychiatry 82: 441-446.
31. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, et al. (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathologica 121: 651-661.
32. Hau P, Stupp R, Hegi ME (2007) MGMT methylation status: The advent of stratified therapy in glioblastoma? Disease Markers 23: 97-104.